retatrutide mechanism triple agonist glp-1 gip glucagon receptor Schematic illustration of monoagonists, dual agonists and retatrutide triple agonist glp-1 gip
Description
In the VESPER series, the company lists three pivotal studies explicitly: VESPER-4 : once-weekly berobenatide in adults with obesity/overweight without type 2 diabetes
The trial enrolled patients aged 6 years and above with obesity and a clinical diagnosis of BBS
Applications Retatrutide: What You Need to Know Its being trialled in individuals with elevated BMI, both with and without diabetes, and preliminary data indicate impressive efficacy
Do not stop taking Mounjaro without consulting your healthcare provider, as abrupt discontinuation could affect your diabetes control
24 This opens the door to exploring these novel compounds as potential therapeutic agents in a broader range of conditions
